Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPT-300 in Major Depressive Disorder
NCT07065240Phase 2Recruiting
- Sponsor
- Seaport Therapeutics
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing SPT-300 with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale-17 Total Score at 42 days. Started Jun 2025; status: recruiting.
02
Drugs
GlyphAllo
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07065240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065240.